Study of Select Combinations in Adults With Myelofibrosis
Status:
Withdrawn
Trial end date:
2024-04-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety, pharmacokinetics (PK) and preliminary
efficacy of both the combination of MBG453 and NIS793 with or without decitabine or
spartalizumab as well as single agent MBG453 and/or NIS793 single agent in myelofibrosis (MF)
subjects post treatment with a Janus Kinase (JAK) inhibitor.
In this study, combination therapies with novel agents including immune therapy will focus on
determining the promising combinations that provide acceptable safety and efficacy
independent of JAK inhibitors. Immune therapy combinations, such as MBG453 in combination
with NIS793, might offer the potential to target MF across genetic heterogeneity.
The primary objective of this study is to characterize the safety, tolerability and
recomended dose for each treatment combination (MBG453 + NIS793, MBG453 + NIS793 +
decitabine, and MBG453 + NIS793 + spartalizumab)